Los Angeles Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Los Angeles Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.75K	Hold	262	–	–	﹤0.01%	1974
2026 Q1	$8.31K	Hold	262	–	–	﹤0.01%	1997
2025 Q4	$6.81K	Buy	+262	New	+$6.9K	﹤0.01%	2212
2025 Q1	–	Sell	-15,421	Closed	-$390K	–	1103
2024 Q4	$390K	Buy	15,421 +8,683	+129%	+$236K	﹤0.01%	872
2024 Q3	$229K	Sell	6,738 -633	-9%	-$24.1K	﹤0.01%	1088
2024 Q2	$273K	Buy	7,371 +638	+9%	+$24.1K	﹤0.01%	1045
2024 Q1	$283K	Buy	+6,733	New	+$276K	﹤0.01%	1022
2023 Q4	–	Sell	-16,082	Closed	-$443K	–	1144
2023 Q3	$443K	Buy	16,082 +56	+0.3%	+$1.75K	﹤0.01%	851
2023 Q2	$544K	Buy	+16,026	New	+$540K	﹤0.01%	827
2014 Q2	–	Sell	-2,435	Closed	-$646K	–	1215
2014 Q1	$646K	Buy	+2,435	New	+$932K	0.01%	789

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's CLDX Position: Q2 2026 in Review

Los Angeles Capital Management held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 262 shares worth $9.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

Los Angeles Capital Management first reported a position in CLDX in Q1 2014 and has held it in 10 quarters since. The position peaked at $646K in Q1 2014. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Los Angeles Capital Management held 262 shares of Celldex Therapeutics worth $9.75K as of Q2 2026.
Los Angeles Capital Management left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1974 holding.
Los Angeles Capital Management first reported a position in Celldex Therapeutics in Q1 2014 and has held it in 10 quarters since.
Los Angeles Capital Management's Celldex Therapeutics position peaked at $646K in Q1 2014.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.